MARKET EYE-Credit Suisse upgrades Dr Reddy's on US outlook

Thu Dec 13, 2012 9:15am IST

Related Topics

Stocks

   

* Credit Suisse upgrades Dr. Reddy's Laboratories to
'outperform' from 'neutral' and raises its target price to 2,150
rupees from 1,900 rupees, citing expectations for a strong pick
up in U.S. sales in the coming quarters.
* Credit Suisse also notes the market share for Dr. Reddy's
Metoprolol drug, used for hypertension, is increasing.
* Dr. Reddy's also expects upcoming approval of two limited
competition products in the United States, Credit Suisse says
after meeting with the drug maker's management.
* Dr. Reddy's also expects fiscal 2015 growth in the United
States to be stronger than fiscal 2014 due to some "significant"
launches.

 (abhishek.vishnoi@thomsonreuters.com /;
abhishek.vishnoi.reuters.com@reuters.net)
FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

India Economy

REUTERS SHOWCASE

Reliance Projects

Reliance Projects

Exclusive: Reliance plans $13 billion projects including new refinery.  Full Article 

Chopper Deal

Chopper Deal

India nears $2.5 billion deal for Boeing military helicopters.  Full Article 

Coal Scam

Coal Scam

CBI drops coal scam case against Kumar Mangalam Birla.  Full Article 

Low Stocks

Low Stocks

Indian power station coal stocks lowest since 2012 blackouts.  Full Article 

Markets This Month

Markets This Month

Tata Motors, M&M top Sensex gainers  Full Article 

Google Drones

Google Drones

Google is testing unmanned drones to deliver anything from dog food to medicine.  Video 

#RiceBucketChallenge

#RiceBucketChallenge

In India, rice replaces ice in bucket challenge.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage